+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Pediatric Epilepsy Therapeutics - Global Strategic Business Report

  • PDF Icon

    Report

  • 184 Pages
  • October 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5991195
The global market for Pediatric Epilepsy Therapeutics was estimated at US$11.7 Billion in 2023, and is projected to reach US$14.7 Billion by 2030, growing at a CAGR of 3.3% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

The growth in the pediatric epilepsy therapeutics market is driven by several factors, including technological advancements, increased awareness and diagnosis of epilepsy, and the rising prevalence of the disorder. Technological innovations, such as the development of wearable seizure detection devices and advanced neuroimaging techniques, are enabling earlier and more accurate diagnosis, which in turn drives demand for effective treatments. The growing understanding of epilepsy’s genetic basis is also propelling the market, as it opens up new possibilities for targeted therapies. Moreover, the increasing availability of healthcare services and improved access to medical care in emerging markets are expanding the addressable market for pediatric epilepsy treatments. Regulatory support for orphan drugs and pediatric-specific formulations is further accelerating the development and approval of new therapies. As these trends continue, the pediatric epilepsy therapeutics market is poised for sustained growth, offering improved treatment options and better outcomes for affected children and their families.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Third Generation Drugs segment, which is expected to reach US$7.0 Billion by 2030 with a CAGR of a 4.1%. The Second Generation Drugs segment is also set to grow at 2.9% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, estimated at $3.2 Billion in 2023, and China, forecasted to grow at an impressive 6.5% CAGR to reach $3.0 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Pediatric Epilepsy Therapeutics Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Pediatric Epilepsy Therapeutics Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Pediatric Epilepsy Therapeutics Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of major players such as Azurity Pharmaceuticals, Inc., Biogen, Inc., Bio-Pharm Solutions Company Limited, and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 86 Featured):

  • Azurity Pharmaceuticals, Inc.
  • Biogen, Inc.
  • Bio-Pharm Solutions Company Limited
  • Eisai Co., Ltd.
  • EpyGenix Therapeutics
  • GSK Plc
  • Jazz Pharmaceuticals Plc
  • Marinus Pharmaceuticals, Inc.
  • Neurelis, Inc.
  • Neurocrine Biosciences, Inc.
  • Praxis Precision Medicines
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Co., Ltd.
  • UCB SA

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • Global Economic Update
  • Pediatric Epilepsy Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Technological Innovations Propel Growth in Pediatric Epilepsy Therapeutics Market
  • Rising Prevalence of Pediatric Epilepsy Expands Addressable Market Opportunity
  • Increased Awareness and Early Diagnosis Drives Demand for Effective Treatments
  • Advances in Genetic Research Strengthen Business Case for Targeted Therapies
  • Development of Wearable Seizure Detection Devices Spurs Market Growth
  • Growing Adoption of Precision Medicine Approaches Drives Adoption of New Therapies
  • Non-Pharmacological Treatments Gain Traction as Complementary Therapies
  • Improved Access to Healthcare Services in Emerging Markets Expands Market Reach
  • Increasing Investment in Pediatric Neurology Research Generates New Opportunities
  • Enhanced Neuroimaging Techniques Accelerate Accurate Diagnosis and Treatment Planning
  • Rising Healthcare Expenditure Supports Sustained Market Growth
  • Evolution of Personalized Treatment Plans Improves Patient Outcomes
  • Increased Focus on Minimizing Side Effects Drives Development of Safer Medications
  • Expansion of Telemedicine Services Creates New Opportunities for Pediatric Epilepsy Care
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Pediatric Epilepsy Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • Table 2: World Recent Past, Current & Future Analysis for Pediatric Epilepsy Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 3: World Historic Review for Pediatric Epilepsy Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 4: World 16-Year Perspective for Pediatric Epilepsy Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
  • Table 5: World Recent Past, Current & Future Analysis for Third Generation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 6: World Historic Review for Third Generation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 7: World 16-Year Perspective for Third Generation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 8: World Recent Past, Current & Future Analysis for Second Generation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 9: World Historic Review for Second Generation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 10: World 16-Year Perspective for Second Generation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 11: World Recent Past, Current & Future Analysis for First Generation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 12: World Historic Review for First Generation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 13: World 16-Year Perspective for First Generation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
  • Pediatric Epilepsy Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • Table 14: USA Recent Past, Current & Future Analysis for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 15: USA Historic Review for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 16: USA 16-Year Perspective for Pediatric Epilepsy Therapeutics by Product Type - Percentage Breakdown of Value Sales for Third Generation, Second Generation and First Generation for the Years 2014, 2024 & 2030
CANADA
  • Table 17: Canada Recent Past, Current & Future Analysis for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 18: Canada Historic Review for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 19: Canada 16-Year Perspective for Pediatric Epilepsy Therapeutics by Product Type - Percentage Breakdown of Value Sales for Third Generation, Second Generation and First Generation for the Years 2014, 2024 & 2030
JAPAN
  • Pediatric Epilepsy Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • Table 20: Japan Recent Past, Current & Future Analysis for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 21: Japan Historic Review for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 22: Japan 16-Year Perspective for Pediatric Epilepsy Therapeutics by Product Type - Percentage Breakdown of Value Sales for Third Generation, Second Generation and First Generation for the Years 2014, 2024 & 2030
CHINA
  • Pediatric Epilepsy Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • Table 23: China Recent Past, Current & Future Analysis for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 24: China Historic Review for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 25: China 16-Year Perspective for Pediatric Epilepsy Therapeutics by Product Type - Percentage Breakdown of Value Sales for Third Generation, Second Generation and First Generation for the Years 2014, 2024 & 2030
EUROPE
  • Pediatric Epilepsy Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • Table 26: Europe Recent Past, Current & Future Analysis for Pediatric Epilepsy Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 27: Europe Historic Review for Pediatric Epilepsy Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 28: Europe 16-Year Perspective for Pediatric Epilepsy Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
  • Table 29: Europe Recent Past, Current & Future Analysis for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 30: Europe Historic Review for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 31: Europe 16-Year Perspective for Pediatric Epilepsy Therapeutics by Product Type - Percentage Breakdown of Value Sales for Third Generation, Second Generation and First Generation for the Years 2014, 2024 & 2030
FRANCE
  • Pediatric Epilepsy Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • Table 32: France Recent Past, Current & Future Analysis for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 33: France Historic Review for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 34: France 16-Year Perspective for Pediatric Epilepsy Therapeutics by Product Type - Percentage Breakdown of Value Sales for Third Generation, Second Generation and First Generation for the Years 2014, 2024 & 2030
GERMANY
  • Pediatric Epilepsy Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • Table 35: Germany Recent Past, Current & Future Analysis for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 36: Germany Historic Review for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 37: Germany 16-Year Perspective for Pediatric Epilepsy Therapeutics by Product Type - Percentage Breakdown of Value Sales for Third Generation, Second Generation and First Generation for the Years 2014, 2024 & 2030
ITALY
  • Table 38: Italy Recent Past, Current & Future Analysis for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 39: Italy Historic Review for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 40: Italy 16-Year Perspective for Pediatric Epilepsy Therapeutics by Product Type - Percentage Breakdown of Value Sales for Third Generation, Second Generation and First Generation for the Years 2014, 2024 & 2030
UNITED KINGDOM
  • Pediatric Epilepsy Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • Table 41: UK Recent Past, Current & Future Analysis for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 42: UK Historic Review for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 43: UK 16-Year Perspective for Pediatric Epilepsy Therapeutics by Product Type - Percentage Breakdown of Value Sales for Third Generation, Second Generation and First Generation for the Years 2014, 2024 & 2030
SPAIN
  • Table 44: Spain Recent Past, Current & Future Analysis for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 45: Spain Historic Review for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 46: Spain 16-Year Perspective for Pediatric Epilepsy Therapeutics by Product Type - Percentage Breakdown of Value Sales for Third Generation, Second Generation and First Generation for the Years 2014, 2024 & 2030
RUSSIA
  • Table 47: Russia Recent Past, Current & Future Analysis for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 48: Russia Historic Review for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 49: Russia 16-Year Perspective for Pediatric Epilepsy Therapeutics by Product Type - Percentage Breakdown of Value Sales for Third Generation, Second Generation and First Generation for the Years 2014, 2024 & 2030
REST OF EUROPE
  • Table 50: Rest of Europe Recent Past, Current & Future Analysis for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 51: Rest of Europe Historic Review for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 52: Rest of Europe 16-Year Perspective for Pediatric Epilepsy Therapeutics by Product Type - Percentage Breakdown of Value Sales for Third Generation, Second Generation and First Generation for the Years 2014, 2024 & 2030
ASIA-PACIFIC
  • Pediatric Epilepsy Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • Table 53: Asia-Pacific Recent Past, Current & Future Analysis for Pediatric Epilepsy Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 54: Asia-Pacific Historic Review for Pediatric Epilepsy Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 55: Asia-Pacific 16-Year Perspective for Pediatric Epilepsy Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
  • Table 56: Asia-Pacific Recent Past, Current & Future Analysis for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 57: Asia-Pacific Historic Review for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 58: Asia-Pacific 16-Year Perspective for Pediatric Epilepsy Therapeutics by Product Type - Percentage Breakdown of Value Sales for Third Generation, Second Generation and First Generation for the Years 2014, 2024 & 2030
AUSTRALIA
  • Pediatric Epilepsy Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
INDIA
  • Pediatric Epilepsy Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
SOUTH KOREAREST OF ASIA-PACIFIC
LATIN AMERICA
  • Pediatric Epilepsy Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
ARGENTINABRAZILMEXICOREST OF LATIN AMERICA
MIDDLE EAST
  • Pediatric Epilepsy Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST
AFRICA
  • Pediatric Epilepsy Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Azurity Pharmaceuticals, Inc.
  • Biogen, Inc.
  • Bio-Pharm Solutions Company Limited
  • Eisai Co., Ltd.
  • EpyGenix Therapeutics
  • GSK Plc
  • Jazz Pharmaceuticals Plc
  • Marinus Pharmaceuticals, Inc.
  • Neurelis, Inc.
  • Neurocrine Biosciences, Inc.
  • Praxis Precision Medicines
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Co., Ltd.
  • UCB SA

Table Information